Illuminating cytochrome P450 binding: Ru(II)-caged inhibitors of CYP17A1

被引：59

作者：

Li, Ao ^{[1
]}

Yadav, Rahul ^{[2
]}

White, Jessica K. ^{[3
]}

Herroon, Mackenzie K. ^{[4
]}

Callahan, Brian P. ^{[5
]}

Podgorski, Izabela ^{[4
,6
]}

Turro, Claudia ^{[3
]}

Scott, Emily E. ^{[2
]}

Kodanko, Jeremy J. ^{[1
,6
]}

机构：

[1] Wayne State Univ, Dept Chem, Detroit, MI 48202 USA

[2] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA

[3] Ohio State Univ, Dept Chem & Biochem, Columbus, OH 43210 USA

[4] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA

[5] Binghamton Univ, Dept Chem, Binghamton, NY 13902 USA

[6] Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA

来源：

CHEMICAL COMMUNICATIONS | 2017年 / 53卷 / 26期

基金：

美国国家科学基金会; 美国国家卫生研究院;

关键词：

PROSTATE-CANCER; VISIBLE-LIGHT; RUTHENIUM(II) COMPLEX; P450; INHIBITORS; CELL-LINES; ABIRATERONE; LIGANDS; 17A1;

D O I：

10.1039/c7cc01459g

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

New Ru(II)-caged abiraterone complexes were synthesized that exhibit strong absorption in the visible region and release the steroidal CYP17A1 inhibitor abiraterone upon exposure to low energy visible light in buffer and prostate cancer cells. Photoinduced release results in abiraterone binding to its CYP17A1 target in an inhibitory mode.

引用

页码：3673 / 3676

页数：4

共 50 条

[41] Ethynyl and Propynylpyrene Inhibitors of Cytochrome P450
Naijue Zhu
Danielle Lightsey
Jiawang Liu
Maryam Foroozesh
Kathleen M. Morgan
Edwin D. Stevens
Cheryl L. Klein Stevens
Journal of Chemical Crystallography, 2010, 40 : 343 - 352
[42] Loss of Cytochrome P450 17A1 Protein Expression in a 17α-Hydroxylase/17,20-Lyase-Deficient 46,XY Female Caused by Two Novel Mutations in the CYP17A1 Gene
Najera, Nayelli
Garibay, Nayely
Pastrana, Yadira
Palma, Icela
Pena, Yolanda-Rocio
Perez, Javier
Coyote, Ninel
Hidalgo, Alberto
Kofman-Alfaro, Susana
Queipo, Gloria
ENDOCRINE PATHOLOGY, 2009, 20 (04) : 249 - 255
[43] P450 CYP17A1 Variant with a Disordered Proton Shuttle Assembly Retains Peroxo-Mediated Lyase Efficiency
Liu, Yilin
Denisov, Ilia G.
Grinkova, Yelena V.
Sligar, Stephen G.
Kincaid, James R.
CHEMISTRY-A EUROPEAN JOURNAL, 2020, 26 (70) : 16846 - 16852
[44] P450C17 (CYP17) DEFICIENCY IN NATIVE MEXICAN PATIENT WITH A NOVEL CYP17A1 MUTATION
Duran Perez, Edgar G.
Gonzalez del Rincon, Lourdes
Moreno Loza, Oscar T.
Martin de Saro, Monica D.
Segovia Palomo, Antonio
Sanchez Pedraza, Valentin
Kofman Alfaro, Susana
Queipo Garcia, Gloria E.
ENDOCRINE PRACTICE, 2011, 17 (01) : 99 - 103
[45] Dietary flavonoids in cancer therapy and prevention: Substrates and inhibitors of cytochrome P450 CYP1 enzymes
Androutsopoulos, Vasilis P.
Papakyriakou, Athanasios
Vourloumis, Dionisios
Tsatsakis, Aristidis M.
Spandidos, Demetrios A.
PHARMACOLOGY & THERAPEUTICS, 2010, 126 (01) : 9 - 20
[46] Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1and colorectal cancer risk
Lara Bethke
Emily Webb
Gabrielle Sellick
Matthew Rudd
Stephen Penegar
Laura Withey
Mobshra Qureshi
Richard Houlston
BMC Cancer, 7
[47] Ru(II)-diimine complexes and cytochrome P450 working hand-in-hand
Eidenschenk, Celine
Cheruzel, Lionel
JOURNAL OF INORGANIC BIOCHEMISTRY, 2020, 213
[48] Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1
Petrunak, Elyse M.
Rogers, Steven A.
Aube, Jeffrey
Scott, Emily E.
DRUG METABOLISM AND DISPOSITION, 2017, 45 (06) : 635 - 645
[49] Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk
Bethke, Lara
Webb, Emily
Sellick, Gabrielle
Rudd, Matthew
Penegar, Stephen
Withey, Laura
Qureshi, Mobshra
Houlston, Richard
BMC CANCER, 2007, 7 (1)
[50] Characterisation of CYP4X1, a novel cytochrome P450
Al-Anizy, M
Bell, DR
TOXICOLOGY, 2004, 202 (1-2) : 100 - 100

← 1 2 3 4 5 →